Format

Send to

Choose Destination
Pathobiology. 2016;83(1):13-23. doi: 10.1159/000440865. Epub 2015 Nov 21.

Gaucher Disease: Clinical, Biological and Therapeutic Aspects.

Author information

1
Laboratory of Biochemistry, Farhat Hached Hospital, Sousse, Tunisia.

Abstract

We present a brief review of Gaucher disease (GD), the most common lysosomal storage disease. GD is a rare autosomal recessive disorder characterized by the defective function of the catabolic enzyme β-glucocerebrosidase (GBA), leading to an accumulation of its substrate, glucocerebroside. Clinical signs and symptoms include neurological dysfunctions, bone infarcts and malformations, hepatosplenomegaly and hypersplenism leading to anemia, neutropenia and thrombocytopenia. Enzyme replacement therapy with recombinant GBA is the mainstay of treatment for GD, which became the first successfully managed lipid storage disease. Future treatments may include oral enzyme replacement and/or gene therapy interventions.

PMID:
26588331
DOI:
10.1159/000440865
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center